Does Thalassemia Increase the Risk of Malignancies?
In this review, researchers evaluated the risk of developing solid and hematologic malignancies in patients with thalassemia.
All articles by John Schieszer, MA
Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Novel Postremission Therapeutic Agents for Patients With Acute Myeloid Leukemia
Results from ongoing trials suggest targeted therapy may improve survival outcomes in acute myeloid leukemia, but further research is needed.
A Changing Landscape: The Future of Treatment for Acute Myeloid Leukemia
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
Optimal Approaches to Treating Venous Thromboembolism in Patients With Cancer
Recent studies suggest that direct-acting oral anticoagulants may be a viable treatment option for cancer patients with VTE, but more research is needed.
Current Standing and Future Directions of CAR T Therapy for Chronic Lymphocytic Leukemia
CAR T therapy has emerged in recent years as a feasible treatment for patients with chronic lymphocytic leukemia, but there are still many unanswered questions.
Better Guidelines for Diagnosing Pulmonary Embolism During Pregnancy Needed
Current guidelines to diagnosis pulmonary embolism in pregnant patients offer conflicting recommendations.
Guideline for Classifying Emetogenicity of Chemotherapy Agents in Pediatric Patients
Researchers classified 49 single-agent and 13 multiple-agent chemotherapy regimens by severity of emetogenicity.
Results From a Phase 2 Study Evaluating Ofatumumab for Advanced-Stage Follicular Lymphoma
Ofatumumab was well tolerated by patients with advanced-stage follicular lymphoma but did not appear superior to other monotherapy agents for this disease.
Influence of Cytogenetics on Outcomes in Relapsed Multiple Myeloma
Researchers were able to gain a better understanding of the clonal genetic landscape of relapsed multiple myeloma following autologous stem cell transplantation.
Next post in Myeloma
